Venom immunotherapy (VIT) for large local reactions (LLR) to insect stings

Conclusions Patients with a history of LLR and positive venom skin tests have <10% risk of future systemic reaction, but often have recurrent LLR. VIT greatly reduced LLR and almost all patients requested to continue VIT. Further studies are required to determine the prevalence of LLR requiring VIT, and the efficacy of VIT.